By Ts. Ng Kuak Ping, FIFST — Lead Formulator & Founder, W.S.T Apotheca · Technical Director, Bionutricia Holding Sdn Bhd (since 2006) · Professional Food Technologist (MBOT) · Registered Food Analyst (Malaysian Food Analysts Council, MOH) · Patent owner, MY188945A · Named inventor on 2023 liposomal encapsulation patent filing Published 3 June 2026 · Last reviewed 3 June 2026 · Author profile → · LinkedIn →
At a glance
Liposomal Vitamin C encapsulates ascorbic acid inside phospholipid vesicles that mimic the cell membrane, bypassing the intestinal absorption ceiling that limits regular supplements. Pharmacokinetic studies show liposomal delivery achieves plasma ascorbate levels approximately 1.77× higher than standard oral vitamin C at equal doses.
Why it matters for immunity: a 2023 Cochrane-updated meta-analysis found vitamin C supplementation reduces common cold duration by 8% in adults under normal conditions and up to 21% under heavy physiological stress. Effect size is dose- and form-dependent: higher bioavailability means the same capsule delivers more usable vitamin C to immune cells.
The patent angle: W.S.T Apotheca founder Ts. Ng Kuak Ping, FIFST holds a 2023 patent filing covering a method for synthesising a bioactive compound integrated with plurality coatings — the liposomal encapsulation technology that underpins Fortheca’s Liposomal Vitamin C. This is not a generic formulation; it is built on proprietary encapsulation methodology developed at Bionutricia.
Fortheca dose: 500 mg/day liposomal ascorbic acid (250 mg/capsule × 2), co-formulated with yeast beta-1,3/1,6-glucan, quercetin, black elderberry, zinc bisglycinate, microencapsulated probiotics, bromelain and vitamin D3.
Why regular vitamin C has an absorption ceiling
Conventional vitamin C tablets and capsules dissolve in the stomach and cross the gut wall via two sodium-dependent vitamin C transporters, SVCT1 and SVCT2. These transporters are saturable: at low doses (under 200 mg) absorption efficiency approaches 90%, but at a single 1 g dose it falls to roughly 50%, and at doses above 3 g to 20% or below. The unabsorbed fraction is excreted rapidly in urine or causes osmotic diarrhoea — the familiar loose-stool symptom of mega-dosing (Carr & Maggini, 2017 — PMC5927356).
This ceiling is why plasma vitamin C levels plateau after a certain daily oral intake regardless of how much you take. For most adults, the plateau is roughly 70–80 µmol/L with 200–400 mg/day oral intake. The bioavailability gap matters because immune cells — neutrophils, lymphocytes, monocytes — actively concentrate ascorbate to levels 10–100× above plasma. Supplying them depends entirely on how much gets absorbed and retained.
How liposomal encapsulation changes the equation
Liposomes are spherical vesicles formed from phospholipids arranged into a bilayer — the same structure as human cell membranes. Encapsulating ascorbic acid inside this bilayer creates several advantages over a plain tablet:
1. Bypasses transporter saturation. Liposomes are absorbed through endocytosis — cellular engulfment — rather than through the SVCT transporters. This route does not saturate.
2. Protected from oxidation in transit. Ascorbic acid is chemically unstable; the phospholipid shell reduces oxidative degradation before the vitamin reaches systemic circulation.
3. Higher plasma levels at equal dose. A 2016 double-blind crossover pharmacokinetic study found that a single liposomal vitamin C dose produced plasma ascorbate AUC 1.77× higher than the identical dose of unencapsulated ascorbic acid (Davis et al., 2016 — PubMed 27072623).
4. Reduced GI side effects. Because less unabsorbed ascorbate reaches the colon, the osmotic burden is lower, allowing higher effective doses without GI disruption.
The formulator’s perspective: the 2023 liposomal patent filing
Most liposomal vitamin C supplements on the market use simple phosphatidylcholine liposomes from sunflower or soy lecithin — a first-generation approach. The difference in Fortheca lies in the encapsulation methodology.
In 2023, Ts. Ng Kuak Ping, FIFST filed a patent at the Malaysian Intellectual Property Corporation for a Method for Synthesizing a Bioactive Compound Integrated with Plurality Coatings. The filing covers a multi-coating encapsulation approach — applying successive protective layers around the bioactive core to improve stability, controlled release, and mucosal absorption, going beyond the single-bilayer liposome standard.
This is the same technology platform applied in Fortheca’s manufacturing process. When a supplement label says “liposomal” without describing the encapsulation architecture, the claim is largely marketing language. When the formulator holds the patent on the encapsulation method, the claim is substantive.
The earlier granted patent, MY188945A (Nutritional Extract Through Biotechnology, 2018), covers the upstream extraction methodology producing the standardized botanical concentrates used across the W.S.T Apotheca line.
Clinical evidence: Vitamin C, immunity and infection
Common cold prevention: A 2023 Cochrane review of 24 trials (over 10,000 participants) found that regular vitamin C supplementation does not significantly reduce cold incidence in the general adult population. However, in people under heavy physical stress (marathon runners, soldiers, skiers), vitamin C reduced cold incidence by 48% — a large, robust effect (Hemilä & Chalker, 2023 — Cochrane CD000980).
Common cold duration: Duration was reduced by approximately 8% in adults and 14% in children who took vitamin C regularly. The effect is modest but consistent across studies.
Immune cell function: Vitamin C accumulates to millimolar concentrations inside neutrophils and lymphocytes. Depleted ascorbate impairs neutrophil motility, phagocytosis, microbial killing, and apoptosis. Supplementation in deficient individuals restores these functions rapidly (Carr & Maggini, 2017).
Beta-glucan synergy: Fortheca co-formulates liposomal Vitamin C with yeast beta-1,3/1,6-glucan — a polysaccharide that binds to dectin-1 receptors on macrophages and neutrophils and primes the innate immune response. A 2021 randomised trial found yeast beta-glucan plus vitamin C reduced cold duration and severity more than either alone (Ware et al., 2021 — PubMed 34527977).
Liposomal vs regular Vitamin C: the honest comparison
| Parameter | Standard oral ascorbic acid | Liposomal Vitamin C |
|---|---|---|
| Absorption mechanism | SVCT1/SVCT2 transporters (saturable) | Endocytosis (non-saturable) |
| Plasma AUC at 1 g dose | Baseline | ~1.77× baseline (Davis 2016) |
| GI tolerance at higher doses | Osmotic diarrhoea above ~2 g single dose | Higher threshold |
| Cost | Lowest | Higher (phospholipid raw material) |
| Who benefits most | Maintenance at ≤500 mg/day | Immune-critical periods, athletes, smokers, post-illness recovery |
Who should consider Fortheca
- Adults who want immune support beyond a basic multivitamin. The co-formulation with beta-glucan, quercetin, zinc and elderberry targets multiple immune pathways simultaneously.
- People who have experienced GI discomfort with high-dose standard Vitamin C. Liposomal form’s lower GI burden allows effective higher doses.
- Those under high physiological stress — athletes, frequent travellers, high-workload professionals — where the evidence for vitamin C on infection incidence is strongest.
- Smokers. Smoking depletes ascorbate rapidly. Liposomal form optimises the corrective supplementation.
Who should NOT take high-dose Vitamin C
- People with haemochromatosis (iron overload). Vitamin C enhances non-haem iron absorption.
- Individuals with G6PD deficiency. High-dose ascorbate can trigger haemolytic anaemia.
- Those with kidney disease or a history of kidney stones. High-dose vitamin C is metabolised to oxalate; doses above 1 g/day may raise stone risk in susceptible individuals.
- Pregnancy. Doses above the established upper tolerable limit are not recommended without medical supervision.
Frequently asked questions
Is “liposomal” just marketing? For some products, yes. The meaningful questions are: what is the phospholipid source and purity? What is the vesicle size? Is there an encapsulation efficiency assay? Fortheca is formulated using the proprietary multi-coating encapsulation methodology covered in the 2023 patent filing by Ts. Ng Kuak Ping, FIFST.
Do I need 1,000 mg of vitamin C per day? The RDA for adults is 75–90 mg/day; the tolerable upper limit is 2,000 mg/day. Fortheca delivers 500 mg/day — within the well-studied range.
Can I take Fortheca with other vitamin C sources? Yes, up to the tolerable upper limit of 2,000 mg/day total from all sources.
How quickly will I feel an immune effect? Vitamin C plasma levels normalise within days. The beta-glucan component primes innate immunity within days of regular dosing. Full adaptive immune benefits require consistent supplementation over weeks to months.
Is there a best time to take Fortheca? With food, morning preferred. The probiotics and bromelain work best when the digestive tract is active.
References
- Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients 2017;9(11):1211. PMC5927356
- Davis JL, et al. Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability. Nutrition and Metabolic Insights 2016;9:25–30. PubMed 27072623
- Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database 2023. CD000980
- Ware LM, et al. Yeast beta-glucan plus vitamin C on upper respiratory tract infections. Nutrients 2021;13(9):3114. PubMed 34527977
- Padayatty SJ, et al. Vitamin C pharmacokinetics. Annals of Internal Medicine 2004;140(7):533–537. PubMed 15068981
This article is for educational purposes and is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication, are pregnant or breastfeeding, or have a diagnosed medical condition.
About the Formulator
Ts. Ng Kuak Ping, FIFST — Lead Formulator & Founder, W.S.T Apotheca · Technical Director, Bionutricia Holding Sdn Bhd (since 2006) · Professional Food Technologist (MBOT) · Registered Food Analyst (MOH) · Patent owner, MY188945A · Named inventor, 2023 liposomal encapsulation patent filing